Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 10 of 10« First...678910

Lonza buys Shire’s U.S. clinical manufacturing site

Lonza Group is acquiring a clinical-stage mammalian manufacturing site in the United States from Shire.

Read More »

RedHill Biopharma’s bowel syndrome drug data fails to impress investors

RedHill Biopharma Ltd. said on Tuesday its drug to treat diarrhea-predominant irritable bowel syndrome met the main goal in a mid-stage study, but the positive data failed to impress investors, sending its U.S.-listed shares lower.

Read More »

EU drugs head fears delays, health hazards as agency uprooted

Access to new medicines and safety checks on existing treatments will be jeopardized if politicians pick a new home for Europe’s London-based drugs regulator that is unacceptable to staff, its executive director told Reuters.

Read More »

Sarepta Jumps Despite DMD Safety Issues in FDA Database

Shares of Sarepta Therapeutics recovered from a dip of about 8 percent as investors seem to have rallied behind the company’s Duchenne muscular dystrophy (DMD) drug Exondys 51.

Read More »

Quest Diagnostics to Pink Slip 538 Shiel Medical Laboratory Employees

Shiel Medial Laboratory will terminate 538 employees at a New Jersey facility following the company’s acquisition by Quest Diagnostics. The layoffs were announced one day after Quest’s acquisition was announced.

Read More »

Celgene Teams Up With Cambridge Biotech Nimbus To Tackle Autoimmune Diseases

Celgene entered into a partnership to take on autoimmune diseases with two of New Jersey-based Nimbus Therapeutics’ preclinical therapeutics.

Read More »

Oxford team to test universal flu vaccine

A seasonal flu vaccine that would be the world’s first to fight all types of the virus will be tested in a two-year study involving 2,000+ patients by Oxford researchers.

Read More »

Shire sues Allergan in U.S. over dry eye drug

Allergan Plc was sued by Shire Plc for allegedly scheming to block doctors from prescribing its new treatment for dry eye disease.

Read More »

FDA moves to smooth path for complex generics

The U.S. FDA announced measures designed to speed to market generic versions of complex drugs in an effort to address the rising costs of pharmaceuticals.

Read More »

How we tick: U.S. ‘body clock’ scientists win Nobel medicine prize

U.S. scientists Jeffrey Hall, Michael Rosbash and Michael Young won the 2017 Nobel prize for medicine for unraveling molecular mechanisms that control our internal body clocks.

Read More »

KSQ Emerges With $76 Million and Will be Helmed by Former Genzyme CEO

David Meeker, the former head of rare diseases for Sanofi Genzyme, left the company in 2017 and reappeared at the helm of gene therapy startup KSQ Therapeutics.

Read More »

Boy Wonder Ramaswamy’s Roivant Bets $116 Million on Arbutus

Shares of Arbutus Biopharma Corporation shot up after biotech investor Vivek Ramaswamy’s Roivant Sciences upped its stake in the company by $116.4 million to advance that company’s hepatitis B program.

Read More »

Ablynx scores big hit with blood disease drug

Belgian biotech company Ablynx reported resoundingly positive data for an experimental drug against a rare blood disorder.

Read More »

Page 10 of 10« First...678910

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2018 Focus: Top 200 Meds, Year After Launch, VR/AR and more!


Ad Right Bottom